After 11 years of listing on the HNX, 13.5 million DBT shares of Ben Tre Pharmaceutical Joint Stock Company (Bepharco) will officially be transferred to the HOSE. Besides setting an important milestone in the company's development journey to affirm and enhance the position of the business, DBT stock is also expected to become more and more attractive when listed on HOSE.
On October 28, 2020, after more than 11 years of listing on the Hanoi Stock Exchange (HNX), 13.5 million DBT shares of Ben Tre Pharmaceutical Joint Stock Company (Bepharco) will move to the house. newly listed on the Ho Chi Minh City Stock Exchange. Ho Chi Minh City (HOSE). In the first session, the opening price of DBT reached 17,000 VND/share, an increase of 2,000 VND compared to the reference price, which is also the price in the last trading session on the HNX.
Not only marking an important milestone for the development process to raise the position, but DBT's share price is also expected to become more and more attractive on HOSE.
BEPHARCO's STRENGTHS
Although it is a medium-sized enterprise in the market compared to many other businesses, Bepharco has more than 40 years of experience in construction and development. From an intra-provincial distribution enterprise, after many stages of equitization and restructuring, Bephar has expanded its business network across the country with a diversified source of both imported and exported products. With the philosophy of "Good medicine - Good health", Bepharco gradually deploys to thoroughly implement this philosophy.
In the past 5 years, Bepharco has expanded into the production of traditional medicine and biological products. Regarding traditional medicine products, Bepharco holds the ownership right of 82.15% of the charter capital of Yen Bai Pharmaceutical Joint Stock Company (Ypharco), a long-standing reputable enterprise in the oriental medicine market with many products trusted by many people. The outstanding product of Ypharco over the past 25 years has been the group of products to treat colds and flu in Huong Xuyen Yen Bai with the WHO-GMP standard of oriental medicine factory for more than 10 years.
With the Bioproducts group, Bepharco currently holds a 51% ownership rate at Nha Trang Vaccine and Biological Products Joint Stock Company (Biopharco), which is an enterprise applying technology transfer for production and trading of biological vaccines. for human use, with the EnteroGolds and EnteroGran biological lines. Biopharco has a factory that meets GMP - WHO standards and is focusing on high quality biological products.
With a commitment to good drug quality in all member enterprises, Bepharco continues to expand into the field of manufacturing and especially to new drugs that meet EU - GMP standards. The company is expected to strongly develop the field of drug research and development for drug production in the factories of the Bepharco system.
Over 30 years of cooperation and development, Bepharco continues to be a reliable partner of Richter, Egis, Sanavita,... in the near future. Imported drugs have always been appreciated and accepted in the Vietnamese market for many years. In the near future, Bepharco will continue to expand imports from developed markets with high quality from its partners, who are the world's leading pharmaceutical companies.
CONTINUOUSLY EXPANDING THE NETWORK OF DISTRIBUTORS
After more than 40 years of expanding its distribution network, Bepharco has more than 20,000 customers who are hospitals spread across Vietnam. With the motto of good medicine business and sustainable development, Bepharco's distribution system gradually brings products to consumers at reasonable prices.
With the business principle of ensuring the health of consumers, Bepharco has won the long-term trust of customers over the years. Currently, Bepharco distributes more than 250 different drug products, and aims to distribute some specific drugs for women and children, continuing its plan to expand its distribution network and focus products on this particular group.
After many years of persistently improving the distribution management system, Bepharco has now applied specific ERP management methods for pharmaceutical distribution by business channels. In the coming time, Bepharco will continue to perfect its distribution system in the direction of Technology and shorten the time it takes to deliver drugs to consumers. The distribution network will be further extended to major cities.
According to Mr. Pham Thu Trieu, General Director of Bepharco, at the present time, Bepharco is at the stage of strong development of the value product chain through the development of specialized products in the system, including product groups. products from traditional medicines to pharmaceutical chemicals and vaccines and biological products. "Bepharco has a wholesale distribution channel covering 63 provinces and cities and a retail system to more than 20,000 drugstores, pharmacies, clinics, and hospitals. Bepharco's distribution capacity has been proven and we are qualified to participate. We focus on developing in-house production and products and thereby control the best and most effective quality and ensure a reasonable price for the community," said Mr. Trieu. strong.
MANY OPPORTUNITIES FOR DBT STOCKS
On October 30, 2009, Bepharco listed 3 million DBT shares on HNX and up to now, the number of shares has increased 4.5 times. The decision to move to list on the HSX is a special milestone for Bepharco, it marks maturity in all aspects, not only in terms of production but also in governance. At the same time, the move from the listing floor to a large-scale "playground" helps elevate the Bepharco brand in the Vietnamese pharmaceutical market.
In the past 4 years, the business situation at Bepharco has been relatively stable with profit after tax reaching VND 25-30 billion. In 2019, consolidated revenue reached VND 794 billion, up 36% compared to 2016 and profit after tax was VND 26 billion, up 8% compared to 2016, the dividend maintained from 8% - 15%. Business goals for the next 4 years are stable revenue growth of 10%/year, average profit growth of 15%/year and dividend of about 10%/year.